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This study assessed and compared the immunogenicity of various immunization strategies in mice using combinations of re-
combinant DNA (pCCMp24) and recombinant attenuated vaccinia virus Tian Tan (rddVTT-CCMp24). Intramuscular immuniza-
tion was performed on days 0 (prime) and 21 (boost). The immunogenicity of the vaccine schedules was determined by meas-
uring human immunodeficiency virus (HIV)-specific binding antibody levels and cytokine (interleukin-2 and interleukin-4) 
concentrations in peripheral blood, analyzing lymphocyte proliferation capacity against HIV epitopes and CD4+/CD8+ cell ratio, 
and monitoring interferon-gamma levels at different times post-immunization. The results showed that pCCMp24, 
rddVTT-CCMp24 and their prime-boost immunization induced humoral and cellular immune responses. The pCCMp24/ 
rddVTT-CCMp24 immunization strategy increased CD8
+ T cells and induced more IFN-γ-secreting cells compared with sin-
gle-shot rDNA. The prime-boost immunization strategy also induced the generation of cellular immunological memory to HIV 
epitope peptides. These results demonstrated that prime-boost immunization with rDNA and rddVTT-CCMp24 had a tendency to 
induce greater cellular immune response than single-shot vaccinations, especially IFN-γ response, providing a basis for further 
studies. 
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Acquired immunodeficiency syndrome (AIDS) is an epi-
demic disease that is difficult to both prevent and treat. De-
signing and developing of an effective preventive or thera-
peutic AIDS vaccine has been a great challenge to public 
health and scientific research. Recent studies in AIDS vac-
cine development have involved using (i) vaccine vectors, 
such as modified vaccinia Ankara (MVA) [1,2], New York 
vaccinia (NYVAC) [3], fowlpox virus (FPV) [4,5], and Ad5 
[6,7], (ii) various human immunodeficiency virus (HIV) 
immunogens, such as gp120 [8], env [9], tat [10], HIV 
multiple epitopes [11–13], and multi-genes [14,15], or (iii) 
different immunization routes and strategies [16,17]. Since 
the first AIDS vaccine trial in 1987, more than 230 vaccine 
trials have been conducted [18]. Unfortunately, most of 
these vaccines failed to induce protection against HIV in-
fection [19]. In a recent phase III clinical trial (RV144) in 
Thailand, using ALVAC-HIV (a recombinant canarypox 
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vector that expresses gag, pol, and env) as prime and 
AIDSVAX B/E (a recombinant gp120 protein) as boost has 
shown 31.2% protective efficacy against HIV. This study 
has provided the first proof-of-concept for a successful HIV 
vaccine [20]. 
Recent studies have focused on developing novel DNA- 
based AIDS vaccines. However, to data, these vaccines 
have failed to confer protective efficacy in non-human pri-
mates and phase I/II human trials. To improve the immu-
nogenicity of DNA-based vaccines, many new delivery 
methods and immunization strategies are being tested, in-
cluding electroporation [21], repetitive vaccine injections 
[22], co-expression of cytokines, such as interleukin-12 (IL- 
12) [23], 4-1BBL [24], or granulocyte-macrophage colony- 
stimulating factor (GM-CSF) [25] as molecular adjuvants, 
and prime-boost immunization strategies using hetero-   
logous vaccines which encode similar antigens [26]. CpG 
oligodeoxynucleotides (ODN) are powerful immunomodu-
latory agents capable of enhancing innate immune respons-
es and when used as an adjuvant to improve adaptive im-
mune responses against pathogens [27–29]. Cholera toxin 
(CT) has the ability to prime memory CD8 T cells, which 
control bacterial and viral challenges [30]. In this study, 
CpG ODN and CT subunit B (CTB) served as adjuvants for 
DNA and recombinant viral vaccines. 
Vaccinia virus-based vaccines expressing HIV-associ- 
ated immunogens can induce both humoral and cellular 
immune responses [31]. In a phase I clinical trial, the re-
combinant virus rMVA expressing HIV-1 virus-like parti-
cles elicited different patterns of T cell and antibody re-
sponses when used alone or in combination with DNA vac-
cine [17]. Several studies have also shown that immune 
responses can be generated in vivo in small animals or 
non-human primates after boost immunization with recom-
binant poxvirus following rDNA [26]. This prime-boost 
strategy using HIV rDNA for priming and recombinant 
vaccinia virus for boosting has been pursued by many re-
searchers. Studies in non-human primate models using the 
SHIV or SIV DNA vaccine for priming and recombinant 
MVA for boosting have demonstrated that this regimen 
helped reduce viral loads in vivo and controlled disease 
progression [3234]. In healthy adults, regimens using a 
multiclade, multigene HIV-1 DNA vaccine for priming and 
MVA for boosting were considered safe and induced broad 
and potent immune responses [35,36]. Recent research has 
shown that rDNA and rMVA vaccines encoding multiple 
cytotoxic and helper T-lymphocyte epitopes of HIV-1 were 
weakly immunogenic but safe in HIV-1-uninfected, vaccinia 
virus-naive adults [37]. 
In the current study, rDNA and attenuated vaccinia virus 
Tian Tan (VTT) vector vaccines were constructed using the 
antigen MEGNp24 developed previously [5,12,38]. Two 
important molecular adjuvants, CpG oligodeoxynucleotides 
(ODN) and cholera toxin subunit B (CTB), were combined 
with the vaccines to further enhance immunogenicity. Im-
munogenicity was evaluated in vitro and in vivo in cell 
models and in mice administered with individual vaccines 
or in combination using the prime-boost regimen. Antigen- 
specific humoral and cellular immune responses were ana-
lyzed for each vaccine regimen. 
1  Materials and methods 
1.1  rDNA and vaccinia virus vaccines 
In the current study, rDNA pVL-CCMp24 (pCCMp24)  
and recombinant attenuated vaccinia virus Tian Tan 
(rddVTT-CCMp24) were prepared as described previously (Du 
et al., data not shown). The vaccines expressed 29 HIV 
dominant epitopes (24 CTL or CD8 T-cell epitopes and five 
B-cell epitopes), HIV-1 p24 protein, CpG ODN (5′- 
AAAAACGTTGACGTTAACGTTGACGTT-3′), and CTB. 
A schematic of the pCCMp24 and rddVTT-CCMp24 constructs 
is shown in Figure 1A. The vaccines were diluted to the 
required concentrations in phosphate-buffered saline (PBS, 
pH 7.4). 
1.2  Immunization of mice 
Six-week-old female BALB/c mice were purchased from 
the Laboratory Animal Center, Academy of Military Medi-
cal Sciences (Beijing, China). All animal experimental pro-
tocols were approved by the Institutional Animal Care and 
Use Committee of the Chinese Academy of Military Medi-
cal Science (10ZDGG007). The mice were divided into four 
groups of eight for immunization. Group 1 was injected 
intramuscularly (i.m.) with 100 μg pCCMp24, group 2  
was injected i.m. with 100 μL of 1×106 PFU mL1        
rddVTT-CCMp24, group 3 was primed i.m. with 100 μg 
pCCMp24 and boosted with 100 μL of 1×106 PFU mL1 
rddVTT-CCMp24, and group 4 was injected i.m. with 100 μL 
PBS. Mice from each group were boosted three weeks after 
the prime vaccination using the same inoculums as for 
priming unless stated otherwise. The immunization schemes 
are shown in Figure 1B. 
1.3  Preparation of splenocytes 
The splenocytes of immunized mice were isolated by cen-
trifugation with Ficoll-Hypaque lymphocyte isolation solu-
tion (TBD Science, China) according to the manufacturer’s 
instructions. In brief, at 10 d post-booster immunization, red 
blood cells were treated with lysis buffer and washed twice 
with complete medium, and the splenocytes were suspended 
in complete culture medium (89% RPMI 1640; HyClone, 
China), 10% fetal bovine serum (HyClone), and 1% penicil-
lin-streptomycin (HyClone). The splenocytes were then 
used for T cell measurements.
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Figure 1  Schematic of pCCMp24 and rddVTT-CCMp24 construction (A) and immunization (B) and HIV specific antibody detection by ELISA (C). A, 
The fusion gene CCMp24 containing CpG ODN, CTB, and the multi-epitope gene (MEG), the 29 epitopes and HIV-1 p24 were inserted into the eukaryotic 
expression vector pVAX1 and expressed under the control of the human cytomegalovirus (CMV) promoter. CCMp24 was also introduced into the TJ2R 
(expressing thymidine kinase)-site of the genome of TE3L-deleted vaccinia virus Tian Tan (VTT) and expressed under vaccinia virus promoter PE/L. B, 
Mice were divided into four groups and vaccinated twice by intramuscular injection. C, ELISA-binding HIV-specific antibody responses elicited with dif-
ferent vaccines and different strategies. The serum samples from each group were collected at 7, 14, 21, and 30 d after vaccination and pre-immunization to 
ascertain anti-HIV IgG by ELISA. The total anti-HIV serum IgG at different periods is illustrated above. All data represent the mean (n=6)±SD. 
1.4  Collection of serum samples 
Blood samples were collected at 7, 14, 21, and 30 d follow-
ing the initial vaccination (prime) and stored at 4°C for 1 h. 
The blood samples were centrifuged at 1000×g for 10 min, 
the sera were recovered and stored at 70°C until required 
for further testing. Sera from pre-immune mice were sepa-
rated and included as the negative control. 
1.5  HIV-specific antibody enzyme-linked immuno-
sorbent assay (ELISA) 
The HIV antibody detection kit (Beijing Wantai Biological 
Pharmacy Enterprise Co., Ltd., Beijing, China) was used to 
measure HIV-1-specific antibody titers. Briefly, 96-well 
ELISA plates were coated with highly purified recombinant 
HIV-1 antigens. One hundred microliter serum samples (test 
samples, as well as positive and negative control sera) were 
added to the appropriate wells, and the plates incubated at 
37°C for 1 h in a humid environment. The plates were 
washed five times with 1× washing buffer and 100 μL 
HRP-conjugate reagent was added. Complex formation was 
permitted to proceed for 30 min at 37°C in a humid envi-
ronment. The plates were washed five times, and 50 μL 
chromogen solutions A and B added to each well. Color 
formation was performed for approximately 30 min in the 
absence of light. Stop solution (50 μL/well) was added to 
each well to conclude the reaction. The absorbance values for 
each well were read at 450 nm using a microplate reader. 
1.6  Interleukin-2 (IL-2) and interleukin-4 (IL-4) 
ELISA assay 
The concentrations of IL-2 and IL-4 present in the peripher-
al blood of mice following booster immunization was 
measured using serum samples harvested at 10 d post- 
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booster immunization using mouse IL-2 and IL-4 ELISA 
kits (GBD, USA) according to the manufacturer’s instruc-
tions. 
1.7  Lymphocyte proliferative assay 
To assess the proliferative response of T lymphocytes 
against HIV-specific peptides, splenocytes were seeded in 
96-well tissue culture plate at a cell density of 2.5×105 
cells/well and co-cultured with HIV-1 peptide pools (gp160, 
VTVYYGVPVWK; Pol, VTIKIGGQLK; Rt, ILKEPVHGV; 
IN, LLWKGEGAV; Vpr, FPRPWLHSL; Tat, RKKRR- 
QRRS; Nef, FPVRPQVPL, at 10 mg L1 per peptide) as a 
specific antigenic stimulator and mitogen ConA as a posi-
tive control, for 72 h at 37°C in the presence of 5% CO2. 
Splenocytes cultured with medium alone (no stimulation) 
served as a negative control. Twenty microliters of WST-1 
solution (Beyotime Institute of Biotechnology, Haimen, 
China) was added to each well and incubated for 4 h, prior 
to agitation for 1 min. The absorbance values were meas-
ured at 450 nm using an ELISA microplate reader. The pro-
liferation of splenocytes was represented by the stimulation 
index (SI): SI=mean absorbance value A450 of stimulated 
cells/mean absorbance value A450 of negative control. 
1.8  CD4+ and CD8+ T-cell subtype assay 
About 1.0×106 splenocytes sampled from mice at 10 d 
post-booster immunization were washed with FACS buffer 
and then stained with PerCP/Cy5.5-labeled anti-mouse CD3, 
fluorescein isothiocyanate-labeled anti-mouse CD4, and 
phycoerythrin-labeled anti-mouse CD8 (BioLegend, CA, 
USA) at 4°C in the dark for 30 min. The samples were 
washed twice, fixed in PBS containing 1% paraformalde-
hyde and analyzed by flow cytometry using Coulter Epics 
XL (Beckman Coulter, USA). Statistical analysis of the 
percentage of CD3+CD4+ and CD3+CD8+ T lymphocytes 
was performed. 
1.9  Interferon-gamma (IFN-γ) enzyme-linked im-
munosorbent spot (ELISPOT) assay 
Vaccine and HIV-specific cellular immune responses in 
mice were evaluated by ELISPOT assay measurements of 
splenocyte IFN-γ secretion following stimulation with 
heat-inactivated recombinant vaccinia virus or HIV CTL 
epitope peptides. Briefly, 1.0×105 splenocytes were plated 
in triplicate in 96-well polyvinylidene difluoride membrane 
plates coated with captured antibody using a mouse IFN-γ 
precoated ELISPOT kit according to the manufacturer’s 
instructions (Dakewe Biotech, Shenzhen, China). The cells 
were stimulated with either 10 μL heat-inactivated     
rddVTT-CCMp24 (1.0×10
6 PFU mL1) or a pool of HIV epitope 
peptides (gp160, VTVYYGVPVWK; Pol, VTIKIGGQLK; 
Rt, ILKEPVHGV; IN, LLWKGEGAV; Vpr, FPRPWLHSL; 
Tat, RKKRRQRRS; Nef, FPVRPQVPL, at 10 mg L1 per 
peptide). Phytohemagglutinin (2.5 μg mL1) was used as the 
positive control. RPMI 1640 was used as the negative con-
trol. After stimulation for 24 h, the cells were washed, 
IFN-γ secreting cells developed using biotinylated antibody 
and streptavidin-HRP, and the cells counted with a Biosys 
Bioreader. 
1.10  Statistical analysis 
Statistical analysis and comparisons between immunization 
groups was performed using Graphpad Prism software (San 
Diego, CA, USA). Data are presented as the mean±standard 
deviation (SD). The significance of differences was calcu-
lated using the One-way ANOVA (two tailed, confidence 
intervals 95%), as indicated by the P-value. Differences 
with a P-value <0.05 were considered to be statistically 
significant.  
2  Results  
2.1  HIV-specific antibody response induced by differ-
ent regimens 
HIV-specific IgG present in the peripheral blood of mice 
immunized with the nominated vaccines and immunization 
strategies was measured at 7, 14, 21, and 30 d post-    
immunization by ELISA (Figure 1B). The results demon-
strated consistent changes in IgG levels between the im-
munized groups and the PBS control group. As shown in 
Figure 1C, at 14 d post-immunization, the total antibody 
levels increased and then decreased. Following booster ad-
ministration at 21 d, HIV-specific IgG levels again in-
creased. At 7 d post-prime, the total antibody levels were 
higher for all vaccine groups analyzed when compared with 
the PBS control group (P<0.05), and the antibody levels 
produced after immunization with rddVTT-CCMp24 (Group 2) 
were markedly higher than for pCCMp24 (Group 1) 
(P<0.05; Figure 1C). For the rDNA/virus prime-boost im-
munization group (Group 3), at 10 d post-boost with 
rddVTT-CCMp24, the antibodies increased faster 1.2 fold than 
for pCCMp24-boost. The above results suggest that 
rddVTT-CCMp24 induced HIV-specific IgG responses, and it 
is obvious that the use of rddVTT-CCMp24 can enhance the 
immune response as a booster. 
2.2  IL-2 and IL-4 secretion induced by different regi-
mens 
The concentration of cytokines IL-2 and IL-4 in the periph-
eral blood of mice was determined using a double antibody 
ELISA. As shown in Figure 2A and B, the concentrations of 
IL-2 and IL-4 were markedly higher for all immunization 
groups analyzed when compared with the PBS control  
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Figure 2  IL-2 and IL-4 levels in peripheral blood measured by ELISA. Three serum samples from each group were collected at 30 d after prime vaccina-
tion and used to determine IL-2 and IL-4 levels (pg mL1). The data represent the mean (n=6)±SD. Asterisks indicate statistically significant differences 
relative to the PBS control; ***, P<0.001. 
group (P<0.01). The results indicated that pCCMp24, 
rddVTT-CCMp24 and their prime-boost regimen all induced 
the generation and secretion of IL-2 and IL-4. 
2.3  Splenic T-lymphocyte proliferation stimulated by 
different regimens 
The proliferation of splenic T-lymphocytes from immunized 
mice was determined by the WST-1 cell proliferation assay. 
Figure 3 shows the SI values determined for splenic T- 
lymphocytes stimulated by HIV epitope peptides (Figure 
3A), or the positive control ConA (Figure 3B). As shown in 
Figure 3A, the stimulation of T-lymphocytes by HIV 
epitope peptides resulted in significant differences in SI 
values for splenocytes from the rddVTT-CCMp24-only vaccine 
group (Group 2) and the rDNA/virus prime-boost group 
(Group 3) when compared with the PBS control group 
(P<0.01). No significant difference in SI values was ob-
served between the rDNA-rDNA group (Group 1) and the 
PBS control group. These results indicate that both 
rVV-rVV and rDNA-rVV could stimulate a T-lymphocyte 
specific proliferative response to HIV peptides. 
2.4  Flow cytometric analysis of splenocytes 
The proportion of CD4+ and CD8+ T cells measured for 
each experimental group are presented in Figure 4. The 
DNA/virus prime-boost group (Group 3) and the rdd- 
VTT-CCMp24-only vaccine group (Group 2) had higher pro-
portions of CD3+CD4+ (P<0.05) and CD3+CD8+ (P<0.01) T 
cells/106 splenocytes than the corresponding PBS control 
group. No significant difference between Group 2 and 
Group 3 was observed. However, the percentage of CD8+ T 
cells for the DNA/virus prime-boost group (Group 3) was 
higher than for both the pCCMp24-only vaccine group 
(Group 1) (P<0.01). In addition, the percentage of CD8+ T 
cells for the rddVTT-CCMp24-only vaccine group was higher 
than for the corresponding pCCMp24-only vaccine group 
(P<0.05). 
2.5  Increased IFN-γ secretion following prime-boost 
immunization and immunologic memory 
To further evaluate the pCCMp24 and rddVTT-CCMp24 
prime-boost immunization strategy, splenocytes from mice 
immunized with pCCMp24- or rddVTT-CCMp24-only vaccine, 
pCCMp24-rddVTT-CCMp24 prime-boost, and PBS control 
were isolated and assessed. The T cell responses were 
measured 30 d after the first immunization (10 d post-boost 
immunization) and at 90 d post-priming, by IFN-γ capture 
ELISPOT assay against inactivated rddVTT-CCMp24 and HIV 
epitope peptides (Figures 5 and 6). At 30 d post-prime im-
munization, and following stimulation with inactivated 
rddVTT-CCMp24, the three immunization groups had on av-
erage greater numbers of IFN-γ-positive spots (SFC)/105 
splenocytes than did the PBS control group (P<0.01). This 
indicated that the immune responses were significantly en-
hanced for all immunization groups when compared with 
the PBS control group (Figures 5A and 6). The rdd- 
VTT-CCMp24-only vaccine group and pCCMp24-rdd- 
VTT-CCMp24 prime-boost group had considerably greater 
numbers of IFN-γ-positive spots (SFC)/105 splenocytes than 
was observed for the pCCMp24-only vaccine group 
(P<0.01). No significant differences were detected between 
Group 2 and Group 3 (Figures 5A and 6). After stimulation 
with HIV epitope peptides, the rddVTT-CCMp24-only vaccine 
group and pCCMp24-rddVTT-CCMp24 prime-boost group had 
greater numbers of SFC/105 splenocytes than both the 
pCCMp24-only and PBS control group (P<0.01; Figures 5B 
and 6). The pCCMp24-rddVTT-CCMp24 prime-boost group 
had greater numbers of SFC/105 splenocytes than did the 
rddVTT-CCMp24-only vaccine group (P<0.01; Figures 5B and  
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Figure 3  Proliferative analysis of splenocyte from mice immunized with pCCMp24, rddVTT-CCMp24, VTT, or PBS at 10 d post-immunization. Approxi-
mately 2.5×105 splenocytes were stimulated with HIV epitope peptides or the positive control ConA. The stimulation index indicates the proliferative capac-
ity of splenocytes from each group when stimulated with different agents. The data represents the mean (n=6)±SD. Asterisks represent statistically signifi-
cant differences; **, P <0.01; ***, P<0.001. 
 
Figure 4  Phenotypic analysis of CD4+ and CD8+ T cells performed with flow cytometry. Splenocytes obtained at 10 d post-immunization from mice im-
munized with rddVTT-CCMp24 or VTT were used to analyze the percentages of CD3
+CD4+ and CD3+CD8+ T cells using flow cytometry. A, Bar graph pre-
senting the percentages of CD3+CD4+ and CD3+CD8+ T cells per 106 splenocytes (mean±SD). Asterisks represent significant differences; *, P<0.05; **, 
P<0.01. B, Representative scatterplots depicting cell surface antigen staining. The percentages of CD3+CD4+ and CD3+CD8+ T cells per 106 splenocytes are 
indicated in the upper right corner. 
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Figure 5  T cell IFN-γ secretion measured by ELISPOT. About 1×105 splenocytes from mice immunized with pCCMp24, rddVTT-CCMp24, VTT, or PBS at 
30 d (A and B) and 90 d (C and D) after prime immunization were stimulated with inactivated rddVTT-CCMp24 (A and C) and HIV CTL epitope peptides (B 
and D). In each panel, the data represent the mean (n=6)±SD. Asterisks represent statistically significant differences; **, P<0.01. 
6). These results indicate that the prime-boost immunization 
strategy could induce greater specific cellular immune re-
sponses than single-shot vaccinations against HIV epitopes. 
At 90 d post-prime immunization (60 d post boost im-
munization), IFN-γ-positive spots (SFC)/105 splenocytes 
were measured for evaluating cellular immunologic 
memory. The average number of IFN-γ-positive spots/105 
splenocytes for all immunization groups was greater against 
inactivated rddVTT-CCMp24 than for the corresponding PBS 
control group (P<0.01; Figure 5C). The pCCMp24- 
rddVTT-CCMp24 prime-boost group had greater numbers of 
SFC/105 splenocytes than did the pCCMp24-only group 
(P<0.05), rddVTT-CCMp24-only group (not significant), and 
PBS group (P<0.01) against HIV epitopes (Figures 5D and 
6). Interestingly, the pCCMp24-only group had higher aver-
age numbers of SFC/105 splenocytes than the rddVTT-CCMp24- 
only group against HIV epitopes (P<0.01; Figure 5D). The-
se results indicate that rddVTT-CCMp24 boost immunization 
following pCCMp24 priming could induce HIV-specific 
cellular immune responses and immunologic memory. 
3  Discussion 
Vaccination has greatly impacted the health of human and 
animals in the past. To date, vaccination still plays a crucial 
role in preventing and controlling infectious diseases and 
cancers. With regard to the development of an effective 
AIDS vaccine, a myriad of problems and challenges have 
been encountered by researchers across a number studies. 
Such challenges include using appropriate animal models 
for vaccine evaluation, and effective immunogen design and 
immunization strategies [19,39,40]. VAX003 and VAX004 
based on recombinant gp120 could not delay disease pro-
gression in phase III human clinical trials, and the antibod-
ies were unable to neutralize most HIV-1 strains [8,41]. 
Considering the high genetic variability of HIV, it seems 
unlikely that a single antigen would prove efficacious in 
protecting against HIV infection and disease progression. 
Therefore, antigen multimers, multi-epitope, or a combina- 
tion of various antigens could be used to address this issue 
and to elicit a strong immune response against HIV [13,15]. 
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Figure 6  Representative IFN-γ spot forming cells under the stimulation of HIV epitope peptides and inactivated rddVTT-CCMp24 are shown. The splenocytes 
were isolated from mice immunized with pCCMp24, rddVTT-CCMp24, VTT, or PBS at 30 and 90 d post-prime immunization. Each spot represents one T 
lymphocyte-secreting IFN-γ. 
In previous study, 29 predominant epitopes of HIV includ-
ing 23 epitopes of HIV-1, three epitopes of HIV-2, a Th cell 
universal epitope, a B cell universal epitope, and a tetanus 
toxin epitope were selected to synthesize and form a fusion 
gene MEGN. The p24 protein of HIV-1 was inserted into 
the multi-epitopes, of the aforementioned fusion gene, and 
named MEGNp24. To enhance the immunogenicity of the 
immunogen, a CpG ODN motif and CTB sequence were 
included upstream of MEGNp24, and the antigen designat-
ed CCMp24. 
Recombinant DNA vaccines and live recombinant virus- 
based vaccines are the focus of many studies. Recent studies 
have documented the use of a number of different vaccines 
including viral vector vaccines or recombinant proteins as a 
boost following priming in an attempt to enhance the im-
mune response induced by a single vaccine. DNA priming 
followed by MVA boosting, and vice versa, may provide 
better protection against malaria infection in mice compared 
with using the DNA or MVA vector alone [42]. In a previ-
ous study, different administration sequences with recom-
binant DNA and recombinant poxvirus were investigated in 
our laboratory. In the present study, virus vector booster 
immunization following priming with DNA was applied. 
Although researchers do not completely understand the 
principle behind the enhanced immune response for 
prime-boost strategies or the reason why priming with the 
recombinant DNA is followed by another modality such as 
viral vector vaccine or recombinant protein, a number of 
studies have documented the use of DNA/live viral recom-
binant in immunization regimens [43]. Several studies in 
non-human primates have demonstrated a significant im-
provement in immunogenicity for a single DNA vaccine 
when a viral vector vaccine was administered as a boost 
following priming [26]. Such synergy between DNA and 
viral vector vaccines was observed in non-human primates 
when used for boosting with poxviruses such as vaccinia 
virus [9,33,34,44,45], Ad5 [46,47] or vesicular stomatitis 
virus [48]. 
Two attenuated vaccinia virus strains, MVA and NYVAC, 
have been used as vectors in vaccine research [3,49,50]. 
MVA-based therapeutic vaccines have been used in the 
treatment of some major chronic infections, including viral 
hepatitis, AIDS, and tuberculosis. Phase 1 and 2 clinical 
trials for MVA-based therapeutic vaccines have started to 
show significant results and promise for the effective treat-
ment of chronic infectious diseases [51]. In rhesus ma-
caques, DNA-MVA vaccine schedules expressing SIVmac- 
239 gag, pr, rt, and env genes, elicited high numbers of 
CD4+ and CD8+ T cells, and high titers and avidity for 
Env-specific IgG [16]. In a recent phase I clinical trial 
(RISVAC02), an MVA-based HIV vaccine expressing the 
env, gag, pol, and nef proteins of HIV-1 subtype B 
(MVA-B) was safe, well tolerated, and elicited strong and 
durable T-cell and antibody responses in 75% and 95% of 
volunteers [52]. The recombinant vaccinia virus vaccine 
rddVTT-CCMp24 used in this study was constructed previously 
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and based on an attenuated vaccinia virus Tian Tan (dele-
tion of TE3L and TK genes). 
In the present study, the immunogenicity of various im-
munization strategies using pCCMp24 and rddVTT-CCMp24 
expressing CTB, HIV multi-epitopes, and p24 protein 
(CCMp24) was investigated in mice. Booster administration 
of the rddVTT-CCMp24 vaccine following DNA priming gen-
erated strong humoral and T cell responses, particularly 
IFN-γ-mediated cellular immune responses against HIV 
peptides. The prime-boost immunization schedule can in-
duced more CD8+ T cells than vaccination with DNA 
(pCCMp24) or virus (rddVTT-CCMp24) alone (Figure 4). In 
addition, rddVTT-CCMp24 booster immunization was neces-
sary following DNA priming to enhance IFN-γ-mediated 
cellular immune responses upon stimulation by HIV peptide 
pools compared with single-shot DNA/DNA or virus/virus 
(Figure 5B and D). There was no significant difference in 
the levels of cytokines (IL-2 and IL-4) in peripheral blood 
for the three different immunization schedules (Figure 2). 
With regard to HIV-specific antibody, rddVTT-CCMp24 
booster immunization following DNA priming induced an-
tibody production more rapidly than for the DNA booster, 
and the antibody levels showed no significant difference 
compared with virus/virus immunization (Figure 1C). These 
data may serve as a basis for future pre-clinical studies of 
recombinant DNA/vaccinia virus immunization schedules. 
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